Orlucent System
Early Detection of Melanoma in Suspicious Moles
Key Facts
About Orlucent
Orlucent is pioneering a novel diagnostic approach for melanoma detection by targeting the biological process of tissue remodeling, a precursor to structural changes in the skin. Its core technology is a point-of-care system that uses a fluorescent peptide dye to bind to the αvβ3 integrin biomarker, associated with neoangiogenesis and stromal remodeling in early melanoma development. The company is currently conducting global clinical trials to validate its technology and establish diagnostic thresholds, positioning itself to address the significant limitations of visual, subjective mole evaluation and reduce unnecessary biopsies. As a private, pre-revenue diagnostics company, Orlucent aims to empower clinicians with real-time, objective data to improve early melanoma detection.
View full company profile